Fig. 3: Cumulative incidence of breakthrough SARS-CoV-2 infection.

Cumulative incidence of SARS-CoV-2 infection in allo-HSCT according to a cell therapy procedure, b use of immunosuppression at the time of first vaccine dose and c conditioning intensity.